Clinical trial
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
NCT02513667
Study timeline
Study start (actual)2015-11-01Date precision: month
Registry last updated2023-02-03
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
ALK-positive Non-small Cell Lung Cancerunresolved
Interventions
CeritinibDRUG · verified · RxNorm: ceritinib
Stereotactic ablative body radiationRADIATION
Sponsors & collaborators
University of Texas Southwestern Medical Centerlead sponsor
Novartis Pharmaceuticalscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02513667 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.